Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies.
Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies.
复制标题
DOI：
10.1042/cs20100297
复制
发表时间：
2011-03
期刊：
影响因子：
--
通讯作者：
Gao Y
中科院分区：
文献类型：
--
作者：
Gui J;Tian Y;Wen X;Zhang W;Zhang P;Gao J;Run W;Tian L;Jia X;Gao Y
循环miRNA（microRNA）正在成为几种病理学状况的有前途的生物标志物，本研究的目的是研究使用血清miRNA作为肝脏病理学生物标志物的可行性。首先采用基于实时qPCR（定量PCR）的TaqMan MicroRNA阵列来分析来自HCC（肝细胞癌）或LC（肝硬化）患者和健康对照的血清池中的miRNA。在HCC、LC、CH B（慢性肝炎B）或GC（胃癌）患者和正常对照中，选择在HCC和LC血清库中上调的5种miRNA（即miR-885- 5 p、miR-574- 3 p、miR-224、miR-215和miR-146 a），并使用实时qPCR进一步定量。本研究发现，血清样本中存在110多种miRNA，且分布范围较广。HCC、LC和CHB患者血清中miR-885- 5 p的水平显著高于健康对照或GC患者。miR-885- 5 p产生0.904 [95%CI（置信区间），0.837-0.951，P<0.0001]的AUC [ROC（受试者操作特征）曲线下面积]，在区分肝脏病理与健康对照方面具有90.53%的灵敏度和79.17%的特异性，使用1.06的截止值（标准化）。在肝脏病理患者中未观察到miR-885- 5 p升高与肝功能参数[AFP（甲胎蛋白）、ALT（丙氨酸氨基转移酶）、AST（天冬氨酸氨基转移酶）和GGT（γ-谷氨酰转肽酶）]之间的相关性。总之，miR-885- 5 p在肝脏病理患者的血清中显著升高，我们的数据表明，血清miRNA可以作为检测和评估肝脏病理的新的互补生物标志物。
Circulating miRNAs (microRNAs) are emerging as promising biomarkers for several pathological conditions, and the aim of this study was to investigate the feasibility of using serum miRNAs as biomarkers for liver pathologies. Real-time qPCR (quantitative PCR)-based TaqMan MicroRNA arrays were first employed to profile miRNAs in serum pools from patients with HCC (hepatocellular carcinoma) or LC (liver cirrhosis) and from healthy controls. Five miRNAs (i.e. miR-885-5p, miR-574-3p, miR-224, miR-215 and miR-146a) that were up-regulated in the HCC and LC serum pools were selected and further quantified using real-time qPCR in patients with HCC, LC, CHB (chronic hepatitis B) or GC (gastric cancer) and in normal controls. The present study revealed that more than 110 miRNA species in the serum samples and wide distribution ranges of serum miRNAs were observed. The levels of miR-885-5p were significantly higher in sera from patients with HCC, LC and CHB than in healthy controls or GC patients. miR-885-5p yielded an AUC [the area under the ROC (receiver operating characteristic) curve] of 0.904 [95% CI (confidence interval), 0.837–0.951, P<0.0001) with 90.53% sensitivity and 79.17% specificity in discriminating liver pathologies from healthy controls, using a cut off value of 1.06 (normalized). No correlations between increased miR-885-5p and liver function parameters [AFP (α-fetoprotein), ALT (alanine aminotransferase), AST (aspartate aminotransferase) and GGT (γ-glutamyl transpeptidase)] were observed in patients with liver pathologies. In summary, miR-885-5p is significantly elevated in the sera of patients with liver pathologies, and our data suggest that serum miRNAs could serve as novel complementary biomarkers for the detection and assessment of liver pathologies.